scholarly article | Q13442814 |
P356 | DOI | 10.1093/JAC/28.SUPPL_B.93 |
P953 | full work available at URL | http://academic.oup.com/jac/article-pdf/28/suppl_B/93/2023885/28-suppl_B-93.pdf |
P698 | PubMed publication ID | 1778896 |
P50 | author | Anthony H. Goldstone | Q110167848 |
P2093 | author name string | S. Blair | |
J. Strang | |||
R. Chopra | |||
K. G. Patterson | |||
P. Cervi | |||
P407 | language of work or name | English | Q1860 |
P921 | main subject | pharmacology | Q128406 |
amphotericin B | Q412223 | ||
P1104 | number of pages | 12 | |
P304 | page(s) | 93-104 | |
P577 | publication date | 1991-10-01 | |
P1433 | published in | Journal of Antimicrobial Chemotherapy | Q6294770 |
P1476 | title | Liposomal amphotericin B (AmBisome) in the treatment of fungal infections in neutropenic patients | |
P478 | volume | 28 Suppl B |
Q40471190 | Amphotericin B Toxicity Reduced by Administration in Fat Emulsion |
Q41378026 | Diversity of lipid-based polyene formulations and their behavior in biological systems |
Q44874051 | Effect of amphotericin B associated with a lipid emulsion on the oxidative burst of human polymorphonuclear leukocytes |
Q36757947 | Effects of the aggregation state of amphotericin B on its toxicity to mice |
Q33606840 | Emerging fungal pathogens, drug resistance and the role of lipid formulations of amphotericin B in the treatment of fungal infections in cancer patients: a review |
Q40965923 | Engineering liposomes for drug delivery: progress and problems |
Q42544559 | In search of the amazing technicolour dream coat for amphotericin B. |
Q72136291 | In vitro and in vivo antifungal activities of liposomal amphotericin B, and amphotericin B lipid complex |
Q35041474 | Interleukin-1beta (IL-1beta) inhibition: a possible mechanism for the anti-inflammatory potency of liposomally conjugated methotrexate formulations in arthritis |
Q43506628 | Lipid emulsion reduces subacute toxicity of amphotericin B: a histopathological study |
Q35372178 | Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics |
Q40899101 | Liposomes as carriers of antimicrobial agents or immunomodulatory agents in the treatment of infections |
Q40485546 | Liposomes in drug delivery. Clinical, diagnostic and ophthalmic potential |
Q40774494 | Management of immunocompromised patients with evidence of an invasive mycosis. |
Q33752450 | Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits |
Q35136556 | Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients |
Q41108756 | Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients |
Q44861655 | The effect of liposomal cefoperazone against Pseudomonas aeruginosa in a granulocytopenic mouse model of acute lung infection |
Q42573016 | Use of nebulised liposomal amphotericin B in the treatment of Aspergillus fumigatus empyema |
Q73013285 | [Amphotericin B deoxycholate (Fungizone): old drug, new versions] |
Q73200587 | [Amphotericin B deoxycholate (Fungizone): old drug, new versions] |
Search more.